PARIS, FRANCE, 18 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors. Read More
Invest Smart Edge
Finance and Investment